Heterocyclic Compounds

Matches 101 - 150 out of 34,040	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/064316A1	COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
WO/2024/060966A1	PAN-KRAS INHIBITOR COMPOUND The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
WO/2024/062250A1	IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS The present invention relates to compounds of Formula (I) that may act as inhibitors of checkpoint kinase 1 (Chk1). The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment o...
WO/2024/061118A1	MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
WO/2024/061333A1	KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are a compound of formula I having KRas inhibitory activity, a pharmaceutical composition comprising the compound, a preparation method therefor, and use thereof. The compound has remarkable selectivity, inhibitory activity, and...
WO/2024/064328A1	COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).
WO/2024/060672A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, an organic electroluminescent device using same, and an electronic apparatus. The organic compound has a structure...
WO/2024/057013A1	NLRP3 MODULATORS Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of NLRP3 and/or the NLRP3 inflammasome. Such compounds are represented by Formula (I), wherei...
WO/2024/056016A1	FREE BASE CRYSTAL FORM OF POLYCYCLIC COMPOUND OF NITROGEN-CONTAINING HETEROCYCLE, AND PREPARATION METHOD THEREFOR The present invention relates to a free base crystal form of a polycyclic compound of a nitrogen-containing heterocycle, and a preparation method therefor. Specifically, the present invention provides a free base crystal form of a compou...
WO/2024/055879A1	CLASS OF FUSED BICYCLIC COMPOUNDS, METHOD FOR PREPARING SAME, AND USE THEREOF Provided are a class of fused bicyclic compounds, a method for preparing same, and use thereof. Particularly, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymo...
WO/2024/056625A1	METHOD FOR PRODUCING MATERIALS FOR USE IN ELECTRONIC DEVICES The invention relates to a method for producing indolo[3,2,1-jk]carbazole and derivatives by reacting a compound of formula (1) and at least one nitrosyl cation source.
WO/2024/057021A1	COMPOUNDS FOR TARGETED PROTEIN DEGRADATION The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
WO/2024/056090A1	PYRROLOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF Disclosed are a pyrrolopyrimidine derivative as an RSK inhibitor and use thereof. Specifically, disclosed are a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, and use of the compound...
WO/2024/059808A1	WEE1 INHIBITORS AND METHODS FOR TREATING CANCER Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive ...
WO/2024/057001A1	COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS The present invention relates to compounds of Formula (I) that may act as agonists of retinoic acid receptor alpha (RAR-α) and/or retinoic acid receptor beta (RAR-β). The invention also relates to pharmaceutical compositions comprising...
WO/2024/059249A1	M4 ACTIVATORS/MODULATORS AND USES THEREOF The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
WO/2024/059010A1	COMPOUNDS FOR TREATING CANCER The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
WO/2023/159307A9	POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
WO/2024/059806A1	BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.
WO/2024/059200A1	NEK7 INHIBITORS Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): (I) or a stereoisomer, tautomer, or salt thereof, wherein A, W, X, Y, Z, R1, and R2 are as defined herein. Methods associated with preparatio...
WO/2024/059163A1	MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME The present invention relates to highly pure and crystalline compounds as starting materials and intermediates to make maralixibat and the processes of making highly pure maralixibat. The invention also relates to an amorphous form of ma...
WO/2024/059607A1	PHYSICAL FORMS OF AN INHIBITOR OF PRC2 The present disclosure relates to physical forms of a PRC2 inhibitor compound, pharmaceutical compositions comprising the physical forms of the compound, and methods of treating subjects having cancer by administering the physical forms,...
WO/2024/059524A1	PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/059186A1	N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.The present invention provides isoquinoline derivatives of for...
WO/2024/054919A1	SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders. Orally available formulations and other ph...
WO/2024/054602A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
WO/2024/051749A1	POLYMORPH OF GLP-1R AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are a polymorph of a GLP-1R agonist compound I, a preparation method therefor, and use thereof. Compared with the free state of the compound I, the polymorph has higher stability and better processability, and is more suitable f...
WO/2024/050635A1	SPIRO-BASED IONIC LIQUID ELECTROLYTE FOR LOW TEMPERATURE SUPERCAPACITORS AND METHODS OF FABRICATING SAME A method for fabricating an ionic liquid electrolyte such as a spiro-based ionic liquid electrolyte, the method has the steps of: synthesizing an intermediate spiro-based product, and applying an ionic exchange process to the intermediat...
WO/2024/051631A1	MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a macrocyclic imidazo[1,2-b]pyridazine compound represented by formula (I) or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer, a tautomer thereof or an isomer mixture thereof, or a...
WO/2024/051816A1	BICYCLIC PRMT5 INHIBITOR Provided is a bicyclic PRMT5 inhibitor, which is a compound having a structure represented by formula (I). Further provided are a preparation method for the compound and use of the compound in regulating PRMT5 activity or treating PRMT5-...
WO/2024/054851A1	MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.
WO/2024/050742A1	BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY Providing certain bifunctional compounds that cause degradation of K-ras G12D via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by K-ras G12D. Also provided are pharmaceutical compositions c...
WO/2024/054952A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
WO/2024/051664A1	SPIRO COMPOUND AND USE Provided are a novel compound having a binding effect with an E3 ligase protein (CRBN), and a use of the compound in the preparation of a drug for treating abnormal cell proliferation diseases.
WO/2024/054647A1	4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-7-NAPHTHALENE-PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF THE KRAS(G12D) MUTANT ONCOPROTEINE FOR THE TREATMENT OF CANCER Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
WO/2024/054512A1	AKT1 MODULATORS Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
WO/2024/051795A1	SUBSTITUTED PURINONE DERIVATIVE USED AS UBIQUITIN-SPECIFIC PROTEASE INHIBITOR The present disclosure relates to a substituted purinone derivative used as a ubiquitin-specific protease inhibitor, and in particular to a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt the...
WO/2024/051308A1	PEMETREXED NEAR-INFRARED FLUORESCENT MOLECULE TARGETING α-TYPE FOLATE RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a pemetrexed near-infrared fluorescent molecule targeting an α-type folate receptor, a preparation method therefor, and use thereof. The structural formula of the pemetrexed near-infrared fluorescent molecule is: . The pem...
WO/2024/050694A1	NATURAL PORPHIN SALT AND USE THEREOF AS PLANT GROWTH REGULATOR AND IMMUNE RESISTANCE INDUCER Disclosed herein are a natural porphin salt and use thereof as a plant growth regulator and an immune resistance inducer. The porphin salt comprises a salt of porphin or a salt of chlorin. Compared with the prior art, the porphin salt of...
WO/2024/052801A1	METHOD FOR PREPARING AMIDINES FROM N-(ALKYL LACTAMS) Method for preparing amidines or derivatives thereof, comprising the step of subjecting N-(amino-alkyl) lactams to dehydration in the presence of a heterogeneous catalyst chosen from a Lewis acid, Lewis acids with Bronsted acid or Bronst...
WO/2024/051727A1	PYRAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION, AND USE The present invention relates to a pyrazole derivative, a pharmaceutical a composition, and a use. The pyrazole derivative has a structure as represented by formula (I). The pyrazole derivative has good activity inhibition selectivity wi...
WO/2024/051778A1	COMPOUNDS, PREPARATION METHODS AND USES THEREOF Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...
WO/2024/051784A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
WO/2024/054956A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain- containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating dis...
WO/2024/054955A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
WO/2024/051702A1	COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF The present invention relates to a compound used as an inhibitor of a CDK4 kinase and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I), wherein the definitions of each group and ...
WO/2024/054954A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
WO/2024/054624A1	MODULATORS OF ALPHA-1 ANTITRYPSIN Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD). (Formula (I))
WO/2024/051668A1	SPIRO COMPOUND AND USE THEREOF Provided are a compound having a binding effect with an E3 ligase protein (CRBN) as represented by formula I and a use of the compound in the preparation of a drug for treating abnormal cell proliferation diseases.
WO/2024/054540A1	LRRK2 INHIBITORS AND USES THEREOF The invention provides pyrazolo[1,5-a][1,3,5]benzotriazepinyl, pyrazolo[1,5-a]pyrido[3,4-f][1,3,5]triazepinyl and related tricyclic compounds that inhibit the activity of one or more kinases, more particularly the protein kinase leucine ...

Matches 101 - 150 out of 34,040	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >